Checkpoint Therapeutics buy melinda
Start price
25.10.18
/
50%
€2.25
Target price
31.10.18
€2.53
Performance (%)
17.27%
End price
31.10.18
€2.63
Summary
This prediction ended on 31.10.18 with a price of €2.63. The BUY prediction by melinda finished with a performance of 17.27%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by melinda for this prediction
In the thread Checkpoint Therapeutics diskutieren
SecteurRecherche biotechnologique et médicale
Operates as a biopharmaceutical company
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.
Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX).
It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP).
The company was founded on November 10, 2014 and is headquartered in New York, NY.
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializes in the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers.
Its portfolio include human immuno-oncology targeted antibodies, which consists of targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR), and and carbonic anhydrase IX (CAIX).
It also develops oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EFGR) mutations; an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4; and an inhibitor of poly (ADP-ribose) polymerase (PARP).
The company was founded on November 10, 2014 and is headquartered in New York, NY.
Nombre d'employés : 6 personnes.
Stopped prediction by melinda for Checkpoint Therapeutics
Checkpoint Therapeutics
Start price
Target price
Perf. (%)
€1.99
12.01.20
12.01.20
-
04.11.21
04.11.21
82.06%
05.11.21
05.11.21
Checkpoint Therapeutics
Start price
Target price
Perf. (%)
€5.84
13.10.17
13.10.17
€8.12
19.12.17
19.12.17
-39.56%
19.12.17
19.12.17
Checkpoint Therapeutics
Start price
Target price
Perf. (%)
€6.47
13.10.17
13.10.17
€9.00
19.12.17
19.12.17
-39.56%
19.12.17
19.12.17